Eton Pharmaceuticals (ETON) Retained Earnings (2017 - 2025)

Eton Pharmaceuticals has disclosed Retained Earnings across 9 years of filings, most recently posting -$112.5 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$112.5 million, down 4.26% year-over-year; the trailing twelve-month figure through Dec 2025 was -$112.5 million (down 4.26% YoY), and the FY2025 annual result was -$112.5 million, down 4.26% from the prior year.
• Retained Earnings came in at -$112.5 million for Q4 2025 at Eton Pharmaceuticals, up from -$114.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$87.0 million in Q1 2021 to a low of -$114.0 million in Q3 2025.
• The 5-year median for Retained Earnings is -$104.1 million (2022), against an average of -$103.1 million.
• Across the five-year window, Retained Earnings decreased 18.85% in 2021 and rose 2.15% in 2023, its largest moves.
• Eton Pharmaceuticals' Retained Earnings stood at -$94.1 million in 2021, then retreated by 9.59% to -$103.1 million in 2022, then declined by 0.91% to -$104.1 million in 2023, then decreased by 3.67% to -$107.9 million in 2024, then dropped by 4.26% to -$112.5 million in 2025.
• The last three Retained Earnings figures came in at -$112.5 million (Q4 2025), -$114.0 million (Q3 2025), and -$112.0 million (Q2 2025), per Business Quant data.